Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study

Abdel G. Babiker, Sean Emery, Gerd Fätkenheuer, Fred M. Gordin, Birgit Grund, Jens D. Lundgren, James D. Neaton, Sarah L. Pett, Andrew Phillips, Giota Touloumi, Michael J. Vjechaj

Research output: Contribution to journalArticlepeer-review

82 Scopus citations

Abstract

Untreated human immunodeficiency virus (HIV) infection is characterized by progressive depletion of CD4+ T lymphocyte (CD4) count leading to the development of opportunistic diseases (acquired immunodeficiency syndrome (AIDS)), and more recent data suggest that HIV is also associated with an increased risk of serious non-AIDS (SNA) diseases including cardiovascular, renal, and liver diseases and non-AIDS-defining cancers. Although combination antiretroviral treatment (ART) has resulted in a substantial decrease in morbidity and mortality in persons with HIV infection, viral eradication is not feasible with currently available drugs. The optimal time to start ART for asymptomatic HIV infection is controversial and remains one of the key unanswered questions in the clinical management of HIV-infected individuals. In this article, we outline the rationale and methods of the Strategic Timing of AntiRetroviral Treatment (START) study, an ongoing multicenter international trial designed to assess the risks and benefits of initiating ART earlier than is currently practiced. We also describe some of the challenges encountered in the design and implementation of the study and how these challenges were addressed. A total of 4000 study participants who are HIV type 1 (HIV-1) infected, ART naïve with CD4 count > 500 cells/µL are to be randomly allocated in a 1:1 ratio to start ART immediately (early ART) or defer treatment until CD4 count is <350 cells/µL (deferred ART) and followed for a minimum of 3 years. The primary outcome is time to AIDS, SNA, or death. The study had a pilot phase to establish feasibility of accrual, which was set as the enrollment of at least 900 participants in the first year. Challenges encountered in the design and implementation of the study included the limited amount of data on the risk of a major component of the primary endpoint (SNA) in the study population, changes in treatment guidelines when the pilot phase was well underway, and the complexities of conducting the trial in a geographically wide population with diverse regulatory requirements. With the successful completion of the pilot phase, more than 1000 participants from 100 sites in 23 countries have been enrolled. The study will expand to include 237 sites in 36 countries to reach the target accrual of 4000 participants. START is addressing one of the most important questions in the clinical management of ART. The randomization provided a platform for the conduct of several substudies aimed at increasing our understanding of HIV disease and the effects of antiretroviral therapy beyond the primary question of the trial. The lessons learned from its design and implementation will hopefully be of use to future publicly funded international trials.

Original languageEnglish (US)
Pages (from-to)S5-S36
JournalClinical Trials
Volume10
DOIs
StatePublished - Jun 2013

Bibliographical note

Funding Information:
The START study is primarily funded by the US National Institutes of Health (NIH grant U01-AI068641) from the Division of Acquired Immunodeficiency Syndrome (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID) for the main study; the Department of Bioethics at the NIH Clinical Center and five NIH institutes: National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); National Institute of Mental Health (NIMH); National Institute of Neurological Disorders and Stroke (NINDS); and the National Institute of Arthritis and Musculoskeletal disorders (NIAMS). Financial support is also provided by the French Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS), the German Ministry of Education and Research, the European AIDS Treatment Network (NEAT), the Australian National Health and Medical Research Council, and the UK Medical Research Council and National Institute for Heath Research. Six pharmaceutical companies (Abbott Laboratories, Inc.; Bristol-Myers Squibb, Gilead Sciences, Inc.; GlaxoSmithKline, Inc.; Merck & Co, Inc.; and Tibotec Pharmaceuticals, Ltd.) have donated over 20 antiretroviral drug formulations to the study’s CDR.

Fingerprint Dive into the research topics of 'Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study'. Together they form a unique fingerprint.

Cite this